John R Cashman

This inventor holds 18 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 3 EPO patents. Top assignees: Human Biomolecular Research Institute, Chemregen, Inc., Burnham Institute for Medical Research. Active years: 2002-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John R Cashman. Retrieved from https://idiyas.com/inventor/john-r-cashman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 1)

% Patents Active = 66.7

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 1.9

ph-index = 3

Forward Citations = 40(Granted Patents)

Location History:

Seattle, WA (US) (2004)
San Diego, CA (US) (2002 - 2023)

Company Filing History:

11 out of 11

Human Biomolecular Research Institute

Burnham Institute for Medical Research

patents

4. 1 out of 99

Sanford-Burnham Medical Research Institute

6. 4 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2023

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11596716 - Compounds and matrices for use in bone growth and repair (2023-03-07),

2. 11492325 - Compounds as inhibitors of sodium channels (2022-11-08),

3. 10874766 - Compounds and matrices for use in bone growth and repair (2020-12-29),

4. 10711037 - Chemical and biochemical adducts as biomarkers for organophosphate exposure (2020-07-14),

5. 10570088 - Blood brain barrier-penetrating oximes for cholinesterase reactivation (2020-02-25),

6. 9751831 - Blood brain barrier-penetrating oximes for cholistenerases reactivation (2017-09-05),

7. 9549991 - Chemical and biochemical adducts as biomarkers for organophosphate exposure (2017-01-24),

8. 9403800 - Compounds for inhibition of cancer cell proliferation (2016-08-02),

9. 9233926 - Compounds for stem cell differentiation (2016-01-12),

10. 9023340 - Wnt inhibitors for human stem cell differentiation (2015-05-05),

11. 9012217 - Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells (2015-04-21),

12. 8906943 - Synthetic compounds and methods to decrease nicotine self-administration (2014-12-09),

13. 8778958 - Synthesis of metabolically stable agents for alcohol and drug abuse (2014-07-15),

14. 8609708 - Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer (2013-12-17),

15. 8481501 - Synthesis of metabolically stable analgesics, pain medications and other agents (2013-07-09),

Title: The Innovative Journey of John R Cashman

Introduction: John R Cashman, a prolific inventor based in San Diego, CA, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: John R Cashman's most recent patents include a revolutionary smart home security system that integrates artificial intelligence for enhanced protection, a cutting-edge medical device for non-invasive monitoring of vital signs, and a sustainable energy solution for rural communities.

Career Highlights: With over 20 years of experience in the tech industry, John R Cashman has a proven track record of developing innovative solutions to complex problems. His expertise lies in the areas of IoT, healthcare technology, and renewable energy.

Collaborations: Throughout his career, John R Cashman has collaborated with leading tech companies, research institutions, and universities to bring his inventions to life. His partnerships have resulted in successful product launches and widespread adoption of his technologies.

Conclusion: John R Cashman's passion for innovation and commitment to creating a positive impact on society have solidified his reputation as a visionary inventor. His relentless pursuit of excellence continues to inspire the next generation of inventors and entrepreneurs in the ever-evolving tech landscape.

Profile summary based on public USPTO records.